Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Follow-up of AbbVie DAA Therapy in Chronic HCV
NCT01773070Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Jun 2013
- Primary completion
- Oct 2016
- Modality
- Allosteric Modulators, Orthosteric Ligands
01
Overview
A Phase 3 trial of paritaprevir, ombitasvir, dasabuvir in hepatitis C (HCV), sponsored by AbbVie Inc.. Started Jun 2013; status: completed.
02
Drugs
paritaprevirombitasvirdasabuvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01773070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01773070.